Why the Radoff-JEC bid for Seer is bigger than a small-cap biotech takeover fight
Find out why Seer’s activist battle could reshape investor thinking on proteomics, diagnostics platforms and biotech value creation.
Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.
Eli Lilly expands genetic medicines toolkit with Engage Bio’s non-viral DNA delivery system
Eli Lilly’s Engage Bio deal is small by its standards, but DNA delivery may become a big battleground in genetic medicines.
XenoTherapeutics’ takeover of Repare wins near-unanimous vote: What’s at stake for the pipeline
Repare shareholders approve XenoTherapeutics deal. Find out how this nonprofit acquisition could reshape oncology pipeline models.